Takara Bio Inc. (4974.T)

1,022.00 +7.00 (+0.69%) At close: 03:15PM JST

Takara Bio Inc.

7-4-38 Nojihigashi
Kusatsu 525-0058
Japan
81 77 565 6920
https://www.takara-bio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,793

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Koichi Nakao	CEO, President & Representative Director	N/A	N/A	1962
Dr. Yoh Hamaoka Ph.D.	CFO, Senior Executive Officer & Director	N/A	N/A	N/A
Mr. Tsuyoshi Miyamura	Senior Managing Executive Officer & Director	N/A	N/A	N/A
Mr. Junichi Mineno Ph.D.	VP, Executive Officer & Director	N/A	N/A	N/A
Katsuhiko Kusakabe	CMCO, Senior Managing Executive Officer & Director	N/A	N/A	N/A
Mr. Andrew Farmer Ph.d.	Head of Research and Development	N/A	N/A	N/A
Akira Kodera	Managing Executive Officer	N/A	N/A	N/A
Kyoko Nakajima	Managing Executive Officer	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Corporate Governance

Takara Bio Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.